814 related articles for article (PubMed ID: 20130243)
21. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms.
Tyner JW; Bumm TG; Deininger J; Wood L; Aichberger KJ; Loriaux MM; Druker BJ; Burns CJ; Fantino E; Deininger MW
Blood; 2010 Jun; 115(25):5232-40. PubMed ID: 20385788
[TBL] [Abstract][Full Text] [Related]
22. Targeting myeloproliferative neoplasms with JAK inhibitors.
Pardanani A; Tefferi A
Curr Opin Hematol; 2011 Mar; 18(2):105-10. PubMed ID: 21245760
[TBL] [Abstract][Full Text] [Related]
23. Dual targeting of JAK2 and ERK interferes with the myeloproliferative neoplasm clone and enhances therapeutic efficacy.
Brkic S; Stivala S; Santopolo A; Szybinski J; Jungius S; Passweg JR; Tsakiris D; Dirnhofer S; Hutter G; Leonards K; Lischer HEL; Dettmer MS; Neel BG; Levine RL; Meyer SC
Leukemia; 2021 Oct; 35(10):2875-2884. PubMed ID: 34480104
[TBL] [Abstract][Full Text] [Related]
24. AKT is a therapeutic target in myeloproliferative neoplasms.
Khan I; Huang Z; Wen Q; Stankiewicz MJ; Gilles L; Goldenson B; Schultz R; Diebold L; Gurbuxani S; Finke CM; Lasho TL; Koppikar P; Pardanani A; Stein B; Altman JK; Levine RL; Tefferi A; Crispino JD
Leukemia; 2013 Sep; 27(9):1882-90. PubMed ID: 23748344
[TBL] [Abstract][Full Text] [Related]
25. Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neoplasms other than myelofibrosis?
Pardanani A; Tefferi A
Leuk Lymphoma; 2014 Dec; 55(12):2706-11. PubMed ID: 25520049
[TBL] [Abstract][Full Text] [Related]
26. Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect.
Choi J; Cooper ML; Alahmari B; Ritchey J; Collins L; Holt M; DiPersio JF
PLoS One; 2014; 9(10):e109799. PubMed ID: 25289677
[TBL] [Abstract][Full Text] [Related]
27. Breakthroughs in myeloproliferative neoplasms.
Santos FP; Verstovsek S
Hematology; 2012 Apr; 17 Suppl 1():S55-8. PubMed ID: 22507780
[TBL] [Abstract][Full Text] [Related]
28. Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.
Choong ML; Pecquet C; Pendharkar V; Diaconu CC; Yong JW; Tai SJ; Wang SF; Defour JP; Sangthongpitag K; Villeval JL; Vainchenker W; Constantinescu SN; Lee MA
J Cell Mol Med; 2013 Nov; 17(11):1397-409. PubMed ID: 24251790
[TBL] [Abstract][Full Text] [Related]
29. JAK2 inhibitors and their impact in myeloproliferative neoplasms.
Geyer HL; Tibes R; Mesa RA
Hematology; 2012 Apr; 17 Suppl 1():S129-32. PubMed ID: 22507800
[TBL] [Abstract][Full Text] [Related]
30. The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.
Mazzacurati L; Lambert QT; Pradhan A; Griner LN; Huszar D; Reuther GW
Oncotarget; 2015 Nov; 6(37):40141-57. PubMed ID: 26472029
[TBL] [Abstract][Full Text] [Related]
31. Myeloproliferative and lymphoproliferative disorders: State of the art.
Rumi E; Baratè C; Benevolo G; Maffioli M; Ricco A; Sant'Antonio E
Hematol Oncol; 2020 Apr; 38(2):121-128. PubMed ID: 31833567
[TBL] [Abstract][Full Text] [Related]
32. SHP2 inhibition displays efficacy as a monotherapy and in combination with JAK2 inhibition in preclinical models of myeloproliferative neoplasms.
Pandey G; Mazzacurati L; Rowsell TM; Horvat NP; Amin NE; Zhang G; Akuffo AA; Colin-Leitzinger CM; Haura EB; Kuykendall AT; Zhang L; Epling-Burnette PK; Reuther GW
Am J Hematol; 2024 Jun; 99(6):1040-1055. PubMed ID: 38440831
[TBL] [Abstract][Full Text] [Related]
33. JAK1/2 and Pan-deacetylase inhibitor combination therapy yields improved efficacy in preclinical mouse models of JAK2V617F-driven disease.
Evrot E; Ebel N; Romanet V; Roelli C; Andraos R; Qian Z; Dölemeyer A; Dammassa E; Sterker D; Cozens R; Hofmann F; Murakami M; Baffert F; Radimerski T
Clin Cancer Res; 2013 Nov; 19(22):6230-41. PubMed ID: 24081976
[TBL] [Abstract][Full Text] [Related]
34. JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms.
Parampalli Yajnanarayana S; Stübig T; Cornez I; Alchalby H; Schönberg K; Rudolph J; Triviai I; Wolschke C; Heine A; Brossart P; Kröger N; Wolf D
Br J Haematol; 2015 Jun; 169(6):824-33. PubMed ID: 25824483
[TBL] [Abstract][Full Text] [Related]
35. The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPN.
Mazzacurati L; Collins RJ; Pandey G; Lambert-Showers QT; Amin NE; Zhang L; Stubbs MC; Epling-Burnette PK; Koblish HK; Reuther GW
Blood Adv; 2019 Nov; 3(22):3503-3514. PubMed ID: 31725895
[TBL] [Abstract][Full Text] [Related]
36. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.
Kleppe M; Kwak M; Koppikar P; Riester M; Keller M; Bastian L; Hricik T; Bhagwat N; McKenney AS; Papalexi E; Abdel-Wahab O; Rampal R; Marubayashi S; Chen JJ; Romanet V; Fridman JS; Bromberg J; Teruya-Feldstein J; Murakami M; Radimerski T; Michor F; Fan R; Levine RL
Cancer Discov; 2015 Mar; 5(3):316-31. PubMed ID: 25572172
[TBL] [Abstract][Full Text] [Related]
37. Janus kinase inhibitors for the treatment of myeloproliferative neoplasms.
Rosenthal A; Mesa RA
Expert Opin Pharmacother; 2014 Jun; 15(9):1265-76. PubMed ID: 24766055
[TBL] [Abstract][Full Text] [Related]
38. Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms.
Gurska LM; Okabe R; Schurer A; Tong MM; Soto M; Choi D; Ames K; Glushakow-Smith S; Montoya A; Tein E; Miles LA; Cheng H; Hankey-Giblin P; Levine RL; Goel S; Halmos B; Gritsman K
Clin Cancer Res; 2023 Mar; 29(5):943-956. PubMed ID: 36537918
[TBL] [Abstract][Full Text] [Related]
39. Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance.
Quintás-Cardama A; Verstovsek S
Clin Cancer Res; 2013 Apr; 19(8):1933-40. PubMed ID: 23406773
[TBL] [Abstract][Full Text] [Related]
40. The role of JAK1/2 inhibitors in the treatment of chronic myeloproliferative neoplasms.
Keohane C; Mesa R; Harrison C
Am Soc Clin Oncol Educ Book; 2013; ():301-5. PubMed ID: 23714529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]